LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK)
- Previous Close
23.550 - Open
25.500 - Bid 20.200 x --
- Ask 20.300 x --
- Day's Range
20.000 - 25.500 - 52 Week Range
13.000 - 26.000 - Volume
4,715,000 - Avg. Volume
305,147 - Market Cap (intraday)
7.004B - Beta (5Y Monthly) -0.58
- PE Ratio (TTM)
26.93 - EPS (TTM)
0.750 - Earnings Date --
- Forward Dividend & Yield 0.62 (2.63%)
- Ex-Dividend Date May 26, 2025
- 1y Target Est
20.04
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the research, development, manufacture, and commercialization of interventional medical devices worldwide. The company offers congenital heart diseases interventional treatment solutions, including atrial septal defect, ventricular septal defect, and patent ductus arteriosus occluder products; delivery systems; and snare products. It also provides cardioembolic stroke prevention solutions, such as left atrial appendage and patent foramen ovale occluder products; treatment of valvular disease solutions comprising aortic valve products, mitral valve products, tricuspid valve products, pulmonary valve products, and procedural accessories; and vascular plugs and interatrial shunt devices. The company offers its products primarily to distributors and hospitals. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. is a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
www.scientechmed.comRecent News: 2291.HK
View More
Performance Overview: 2291.HK
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2291.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2291.HK
View MoreValuation Measures
Market Cap
8.17B
Enterprise Value
6.98B
Trailing P/E
31.56
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.47
Price/Book (mrq)
3.89
Enterprise Value/Revenue
14.09
Enterprise Value/EBITDA
23.06
Financial Highlights
Profitability and Income Statement
Profit Margin
52.06%
Return on Assets (ttm)
7.85%
Return on Equity (ttm)
12.52%
Revenue (ttm)
471.64M
Net Income Avi to Common (ttm)
245.56M
Diluted EPS (ttm)
0.750
Balance Sheet and Cash Flow
Total Cash (mrq)
1.13B
Total Debt/Equity (mrq)
0.08%
Levered Free Cash Flow (ttm)
--